This systematic retrospective study, including nine randomized controlled trials of more than 500 patients, provides evidence that a relatively short course of glucocorticoid therapy for IgA nephropathy reduces the risk of renal failure by two-thirds compared with supportive therapy or angiotensin-converting enzyme inhibitor therapy alone [10, 26]. This evidence concerns the gene ACE and Renal insufficiency.